Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Duell, Johannes, Abrisqueta, Pau, Andre, Marc, Gaidano, Gianluca, Gonzales-Barca, Eva, Jurczak, Wojciech, Kalakonda, Nagesh, Liberati, Anna Marina, Maddocks, Kami J, Menne, Tobias, Nagy, Zsolt, Tournilhac, Olivier, Kuffer, Christian, Bakuli, Abhishek, Amin, Aasim, Gurbanov, Konstantin, Salles, Gilles
Published in Haematologica (Roma) (01.02.2024)
Published in Haematologica (Roma) (01.02.2024)
Get full text
Journal Article
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study
Duell, Johannes, Abrisqueta, Pau, Andre, Marc, Gaidano, Gianluca, Gonzales-Barca, Eva, Jurczak, Wojciech, Kalakonda, Nagesh, Liberati, Anna Marina, Maddocks, Kami J, Menne, Tobias, Nagy, Zsolt, Tournilhac, Olivier, Kuffer, Christian, Bakuli, Abhishek, Amin, Aasim, Gurbanov, Konstantin, Salles, Gilles
Published in Haematologica (Roma) (31.08.2023)
Published in Haematologica (Roma) (31.08.2023)
Get full text
Journal Article